Floor & Decor · 2027 Benefits Renewal

Floor & Decor's 2027 renewal: the oncology line item

Cancer is the fastest-growing line on a self-funded plan — and your August renewal locks it for a year. Here's what it looks like for a ~13,700-person plan.

A 1% improvement on Floor & Decor's plan is worth
~$2.4M / year
That's the prize ClearOnc goes after — every renewal, every year.
Total annual plan spend
~$240M
~13,700 employees × $17,496 national avg cost.
Estimated oncology spend
~$57M
23.9% of plan spend — and rising 7–9% a year.
Single-claim exposure
$4.3M
Highest single cancer claim in 2024. Self-funded, it lands on you.

Why a retail + warehouse plan carries hidden cancer cost

Your workforce skews older and hourly — the profile that concentrates cancer incidence. And when a complex case isn't navigated from day one, the cost compounds: wrong site of care, specialty drugs that don't match the tumor, avoidable admissions, and the attrition of a worker you then re-hire and re-train.

ClearOnc is the navigator that closes that gap. Moffitt-powered: we route members to the right diagnosis path, the right site of care, and the right specialty-drug pathway — before the dollars leak. The result is a measurable dent in the line that's growing faster than any other on your plan.

Where the 1% hides

The gaps that quietly inflate the oncology line in plans like yours — each one is something ClearOnc closes.

1 in 3
cancer patients ever get a survivorship care plan — driving avoidable recurrence cost.
8%
of lung-cancer patients get full NCCN biomarker testing — so plans fund therapies that can't work.
11 of 20
costliest injectable drugs treat cancer — specialty-drug routing is where dollars leak.
>50%
of working patients get no flex hours or paid leave — driving turnover you re-hire for.

20 minutes, before your August renewal

We'll walk Floor & Decor's actual oncology exposure and show exactly where the 1% hides.

Book your oncology spend review → Run your full breakdown